Quick Answer
Unicycive Therapeutics, Inc. reported Operating Income of -$29.52 million for fiscal year 2025.
Unicycive Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$29.52M | +8.1% |
| 2024 | -$32.12M | -54.6% |
| 2023 | -$20.77M | -15.1% |
| 2022 | -$18.05M | -101.1% |
| 2021 | -$8.98M | -344.4% |
| 2020 | -$2.02M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.34M | -17.5% | -5.4% |
| June 30, 2025 | -$6.96M | +5.9% | +12.8% |
| March 31, 2025 | -$7.99M | +13.2% | -27.8% |
| September 30, 2024 | -$6.25M | -5.3% | +15.5% |
| June 30, 2024 | -$7.40M | -71.2% | +19.6% |
| March 31, 2024 | -$9.20M | -119.0% | -55.0% |
| September 30, 2023 | -$5.94M | -6.9% | -37.4% |
| June 30, 2023 | -$4.32M | -18.9% | -2.9% |
- Unicycive Therapeutics, Inc. showed an increase of +8.1% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Unicycive Therapeutics, Inc.’s operating income has declined by 1361.2% (from -$2.02 million to -$29.52 million).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: